Reuters logo
5 months ago
BRIEF-Oncogenex Pharma believes cash, cash equivalents, short-term investments to be sufficient to fund currently planned operations for next 12 months
February 23, 2017 / 2:33 PM / 5 months ago

BRIEF-Oncogenex Pharma believes cash, cash equivalents, short-term investments to be sufficient to fund currently planned operations for next 12 months

1 Min Read

Feb 23 (Reuters) - Oncogenex Pharmaceuticals Inc:

* Oncogenex pharma - believes cash, cash equivalents, short-term investments to be sufficient to fund currently planned operations for at least next 12 months

* Oncogenex pharmaceuticals inc - revenue for q4 was zero

* Oncogenex pharmaceuticals inc - net loss for q4 and year ended december 31, 2016 was $5.8 million and $20.1 million, respectively Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below